# Purui Jizhun Technology (Beijing)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/purui-jizhun-technology-beijing

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.precisionscientific.com
- Total disclosed funding: $23M
- Latest round: Series D (Dec 9, 2025)
- Investors on record: 13

## About

Established in 2015 and based in Beijing, China, Precision Scientific Technology (Beijing) Co., Ltd., trading as Purui Jizhun Technology (Beijing), operates as a biological information solution provider that focuses on innovative drugs. It has established the office,  Lab & GMP Factory in Suzhou, and a Laboratory in Beijing. Xuwo Ji, the founder, and CEO, graduated from Peking University, and he has over 10 years of investment experience in healthcare and life sciences. In December 2025, Purui Jizhun Technology (Beijing) raised a series D funding from new investors Hongyuan Huifu Capital, GIG Capital Management Group, SND Ventures Group and returning investor Shenzhen Salubris Pharmaceuticals.
The company provides data-driven solutions for precision oncology research and drug development, including drug target discovery, biomarker identification, indication selection, drug resistance mechanism investigation, and combination therapy recommendation. It has developed a data analytics platform, AIBERT®, which is an AI-driven tool focusing on multi-omics data mining and predictive algorithms. The company also provides integrated CRO services, including central laboratory full-services, companion diagnostic development and commercialization, and regulatory strategy.
The company's revenue is generated by providing high-throughput genomic sequencing and bioinformatics big data analysis, dedicated to providing comprehensive, accurate, and highly customized personalized medical solutions, applying to precision medicine for cancer, providing comprehensive and accurate individualized treatment plans and genetic risk assessments for cancer patients, and offering the most advanced and optimized research service solutions for researchers in the field of oncology.
The Series D financing will help the company further expand its business scale, strengthen technological research and development, and improve its service capabilities, providing high-quality translational medicine solutions to more pharmaceutical companies and clinical users.

## Funding rounds

- Series D, Dec 9, 2025 — SND Ventures Group, GIG Capital Management Group, Shenzhen Salubris Pharmaceuticals, Hongyuan Huifu Capital
- Series B, Jan 31, 2022 — SND Ventures Group
- Series B, Sep 18, 2021, $23M — GTJA Investment Group, Maison Capital, Innovation Works, Kington Capital, Polaris Capital, Grand Mount Capital
- Series A, Oct 26, 2020 — Baidu Ventures
- Angel, May 7, 2018 — CD Capital, Watson Capital

## Investors

- CD Capital — Angel
- Watson Capital (https://capitalatlas.ai/funds/watson-capital) — Angel
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series A
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series B
- Maison Capital (https://capitalatlas.ai/funds/maison-capital) — Series B
- Innovation Works (https://capitalatlas.ai/funds/innovation-works) — Series B
- Kington Capital (https://capitalatlas.ai/funds/kington-capital) — Series B
- Polaris Capital (https://capitalatlas.ai/funds/polaris-capital) — Series B
- Grand Mount Capital (https://capitalatlas.ai/funds/grand-mount-capital) — Series B
- SND Ventures Group (https://capitalatlas.ai/funds/snd-ventures-group) — Series B, Series D
- GIG Capital Management Group — Series D
- Shenzhen Salubris Pharmaceuticals — Series D
- Hongyuan Huifu Capital (https://capitalatlas.ai/funds/hongyuan-huifu-capital) — Series D